AN2 Therapeutics (ANTX)

Executive Summary

AN2 Therapeutics is a clinical-stage biopharmaceutical company leveraging its proprietary boron chemistry platform to develop oral treatments for rare, chronic infectious diseases with high unmet need. The company’s primary focus is Chagas disease, a neglected tropical condition with no approved therapies in the U.S. AN2 also has a pipeline of epetraborole, a boron-based antibiotic, targeting nontuberculous mycobacterial (NTM) infections. Following the termination of a Phase 2/3 trial in refractory MAC lung disease due to futility, AN2 has shifted focus to a Phase 2 study in Mycobacterium abscessus infections (NCT07301320), which began recruiting in March 2026. The company is also advancing a novel compound, AN2-502998, through Phase 1 healthy volunteer studies (NCT07024589), expected to complete in April 2026. With a talented team experienced in boron chemistry and infectious disease drug development, AN2 aims to deliver first-in-class medicines for underserved patient populations. The recent pipeline pivot reflects a strategic response to clinical setbacks, but the company retains potential value through its platform and upcoming data readouts.

Upcoming Catalysts (preview)

• Q2 2026Phase 1 data for AN2-502998 (healthy volunteers)80% success
• Q4 2026Phase 2 enrollment update for epetraborole in M. abscessus60% success
• H2 2026Chagas disease program initiation (IND filing or Phase 1 start)50% success